Indicators of Response to the Wee1 Inhibitor Adavosertib in Acute Myeloid Leukemia

被引：0
作者：
Srivastava, Ankita [1 ]
Heckman, Caroline A. [1 ,2 ,3 ,4 ,5 ,6 ]
Miettinen, Juho Jalmari [3 ]
Harismendy, Olivier [7 ]
机构：
[1] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland
[2] Inst Mol Med Finland FIMM, Helsinki, Finland
[3] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki Inst Life Sci, Helsinki, Finland
[4] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki Inst Life Sci, ICAN Digital Precis Canc Med Flagship, Helsinki, Finland
[5] Univ Helsinki, Inst Mol Med Finland FIMM, HiLIFE, Helsinki, Finland
[6] Univ Helsinki, ICAN Digital Precis Canc Ctr Med Flagship, Helsinki, Finland
[7] Zentalis Pharmaceut, Translat Data Sci & Computat Biol, San Diego, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-188608
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
[31]   A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma. [J].
Liu, Joyce F. ;
Xiong, Niya ;
Campos, Susana M. ;
Wright, Alexi A. ;
Krasner, Carolyn N. ;
Schumer, Susan T. ;
Horowitz, Neil S. ;
Veneris, Jennifer Taylor ;
Tayob, Nabihah ;
Morrissey, Stephanie ;
West, Gabriela ;
Quinn, Roxanne ;
Matulonis, Ursula A. ;
Konstantinopoulos, Panagiotis A. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[32]   WEE1 kinase inhibitor shows promise [J].
Sidaway, Peter .
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (10) :593-593
[33]   CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells [J].
Qi, Wenxiu ;
Xie, Chengzhi ;
Li, Chunhuai ;
Caldwell, J. Timothy ;
Edwards, Holly ;
Taub, Jeffrey W. ;
Wang, Yue ;
Lin, Hai ;
Ge, Yubin .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
[34]   CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells [J].
Wenxiu Qi ;
Chengzhi Xie ;
Chunhuai Li ;
J Timothy Caldwell ;
Holly Edwards ;
Jeffrey W Taub ;
Yue Wang ;
Hai Lin ;
Yubin Ge .
Journal of Hematology & Oncology, 7
[35]   Synergistic Effects of Adavosertib, WEE-1 Inhibitor in Combination with Cytarabine in the Jurkat Leukemia Cell Model [J].
Rodriguez-Vazquez, Gabriel O. ;
Diaz-Quinones, Adriana O. ;
Salgado, Iris K. ;
Ortiz, Walter I. Silva ;
Maldonado, Hector M. .
FASEB JOURNAL, 2022, 36
[36]   CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo [J].
Chaudhuri, Leena ;
Vincelette, Nicole D. ;
Koh, Brian D. ;
Naylor, Ryan M. ;
Flatten, Karen S. ;
Peterson, Kevin L. ;
McNally, Amanda ;
Gojo, Ivana ;
Karp, Judith E. ;
Mesa, Ruben A. ;
Sproat, Lisa O. ;
Bogenberger, James M. ;
Kaufmann, Scott H. ;
Tibes, Raoul .
HAEMATOLOGICA, 2014, 99 (04) :688-696
[37]   WEE1 kinase inhibitor shows promise [J].
Peter Sidaway .
Nature Reviews Clinical Oncology, 2019, 16 :593-593
[38]   Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells [J].
Okabe, Seiichi ;
Moriyama, Mitsuru ;
Gotoh, Akihiko ;
Akahane, Daigo .
DISCOVER ONCOLOGY, 2025, 16 (01)
[39]   Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia [J].
Di Rora, Andrea Ghelli Luserna ;
Bocconcelli, Matteo ;
Ferrari, Anna ;
Terragna, Carolina ;
Bruno, Samantha ;
Imbrogno, Enrica ;
Beeharry, Neil ;
Robustelli, Valentina ;
Ghetti, Martina ;
Napolitano, Roberta ;
Chirumbolo, Gabriella ;
Marconi, Giovanni ;
Papayannidis, Cristina ;
Paolini, Stefania ;
Sartor, Chiara ;
Simonetti, Giorgia ;
Yen, Timothy J. ;
Martinelli, Giovanni .
CANCERS, 2019, 11 (11)
[40]   Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma [J].
Cole, Kristina A. ;
Ijaz, Heba ;
Surrey, Lea F. ;
Santi, Mariarita ;
Liu, Xiaowei ;
Minard, Charles G. ;
Maris, John M. ;
Voss, Stephan ;
Reid, Joel M. ;
Fox, Elizabeth ;
Weigel, Brenda J. .
CANCER, 2023, 129 (14) :2245-2255
12345